• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

Characterization of wild-type human medium-chain acyl-CoA dehydrogenase (MCAD) and mutant enzymes present in MCAD-deficient patients by two-dimensional gel electrophoresis: evidence for post-translational modification of the enzyme.

作者信息

Bross P, Jensen T G, Andresen B S, Kjeldsen M, Nandy A, Kølvraa S, Ghisla S, Rasched I, Bolund L, Gregersen N

机构信息

Center for Medical Molecular Biology, Aarhus University Hospital, Skejby Sygehus, Denmark.

出版信息

Biochem Med Metab Biol. 1994 Jun;52(1):36-44. doi: 10.1006/bmmb.1994.1031.

DOI:10.1006/bmmb.1994.1031
PMID:7917465
Abstract

Two-dimensional gel electrophoresis was used to study and compare wild-type medium-chain acyl-CoA dehydrogenase (MCAD; EC 1.3.99.3) and mis-sense mutant enzyme found in patients with MCAD deficiency. By comparing the patterns for wild-type and mutant MCAD expressed in Escherichia coli or in eukaryotic COS-7 cells we demonstrate that variants with point mutations changing the net charge of the protein can be readily resolved from the wild-type protein. After expression of the cDNA in eukaryotic cells two spots representing mature MCAD can be distinguished, one with an isoelectric point (pI) corresponding to that obtained for the mature protein expressed in E. coli and another one shifted to lower pI. This demonstrates that MCAD protein is partially modified after transport into the mitochondria and removal of the transit peptide. The observed pI shift would be compatible with phosphorylation of one aspartic acid residue per monomer. Comparison of pulse labeling and steady-state amounts of MCAD protein in overexpressing COS-7 cells confirms that K304E MCAD is synthesized and transported into mitochondria in amounts similar to the wild-type protein, but is degraded much more readily. For wild-type MCAD, the spot representing the nonmodified form predominates after pulse labeling while that representing the modified form is relatively stronger in steady state, demonstrating that the modification occurs in mitochondria after the transit peptide has been removed. For K304E mutant MCAD, the nonmodified spot is relatively stronger both in pulse labeling and in steady state, indicating that either the efficiency of modification or the stability of the modified form is affected by the K304E mutation.(ABSTRACT TRUNCATED AT 250 WORDS)

摘要

相似文献

1
Characterization of wild-type human medium-chain acyl-CoA dehydrogenase (MCAD) and mutant enzymes present in MCAD-deficient patients by two-dimensional gel electrophoresis: evidence for post-translational modification of the enzyme.
Biochem Med Metab Biol. 1994 Jun;52(1):36-44. doi: 10.1006/bmmb.1994.1031.
2
Co-overexpression of bacterial GroESL chaperonins partly overcomes non-productive folding and tetramer assembly of E. coli-expressed human medium-chain acyl-CoA dehydrogenase (MCAD) carrying the prevalent disease-causing K304E mutation.细菌GroESL伴侣蛋白的共表达部分克服了携带常见致病K304E突变的大肠杆菌表达的人线粒体中链酰基辅酶A脱氢酶(MCAD)的非生产性折叠和四聚体组装。
Biochim Biophys Acta. 1993 Oct 20;1182(3):264-74. doi: 10.1016/0925-4439(93)90068-c.
3
Effects of two mutations detected in medium chain acyl-CoA dehydrogenase (MCAD)-deficient patients on folding, oligomer assembly, and stability of MCAD enzyme.
J Biol Chem. 1995 Apr 28;270(17):10284-90. doi: 10.1074/jbc.270.17.10284.
4
Disease-causing mutations in exon 11 of the medium-chain acyl-CoA dehydrogenase gene.中链酰基辅酶A脱氢酶基因第11外显子中的致病突变。
Am J Hum Genet. 1994 Jun;54(6):975-88.
5
Impaired tetramer assembly of variant medium-chain acyl-coenzyme A dehydrogenase with a glutamate or aspartate substitution for lysine 304 causing instability of the protein.304位赖氨酸被谷氨酸或天冬氨酸替代的变异型中链酰基辅酶A脱氢酶四聚体组装受损,导致蛋白质不稳定。
J Biol Chem. 1992 Dec 25;267(36):26004-10.
6
Expression of wild-type and mutant medium-chain acyl-CoA dehydrogenase (MCAD) cDNA in eucaryotic cells.野生型和突变型中链酰基辅酶A脱氢酶(MCAD)cDNA在真核细胞中的表达。
Biochim Biophys Acta. 1992 Oct 13;1180(1):65-72. doi: 10.1016/0925-4439(92)90028-l.
7
Expression and characterization of human mutant (glutamic acid304) medium-chain acyl-coenzyme A dehydrogenase in mammalian cells.人突变型(谷氨酸304)中链酰基辅酶A脱氢酶在哺乳动物细胞中的表达与特性分析
Pediatr Res. 1993 Nov;34(5):694-7. doi: 10.1203/00006450-199311000-00025.
8
A rare disease-associated mutation in the medium-chain acyl-CoA dehydrogenase (MCAD) gene changes a conserved arginine, previously shown to be functionally essential in short-chain acyl-CoA dehydrogenase (SCAD).中链酰基辅酶A脱氢酶(MCAD)基因中的一种罕见疾病相关突变改变了一个保守的精氨酸,此前已证明该精氨酸在短链酰基辅酶A脱氢酶(SCAD)中具有功能重要性。
Am J Hum Genet. 1993 Sep;53(3):730-9.
9
Biosynthesis of variant medium chain acyl-CoA dehydrogenase in cultured fibroblasts from patients with medium chain acyl-CoA dehydrogenase deficiency.中链酰基辅酶A脱氢酶缺乏症患者培养成纤维细胞中变异型中链酰基辅酶A脱氢酶的生物合成
Pediatr Res. 1986 Sep;20(9):843-7. doi: 10.1203/00006450-198609000-00007.
10
Molecular diagnosis and characterization of medium-chain acyl-CoA dehydrogenase deficiency.
Scand J Clin Lab Invest Suppl. 1995;220:9-25.

引用本文的文献

1
A gene therapy targeting medium-chain acyl-CoA dehydrogenase (MCAD) did not protect against diabetes-induced cardiac pathology.一种针对中链酰基辅酶A脱氢酶(MCAD)的基因疗法并不能预防糖尿病诱发的心脏病变。
J Mol Med (Berl). 2024 Jan;102(1):95-111. doi: 10.1007/s00109-023-02397-2. Epub 2023 Nov 21.
2
Selected reaction monitoring as an effective method for reliable quantification of disease-associated proteins in maple syrup urine disease.选择反应监测作为可靠定量枫糖尿症中疾病相关蛋白质的有效方法。
Mol Genet Genomic Med. 2014 Sep;2(5):383-92. doi: 10.1002/mgg3.88. Epub 2014 Jun 4.
3
Biochemical characterization of a variant human medium-chain acyl-CoA dehydrogenase with a disease-associated mutation localized in the active site.
一种具有位于活性位点的疾病相关突变的变异型人线粒体中链酰基辅酶A脱氢酶的生化特性
Biochem J. 1999 Jan 15;337 ( Pt 2)(Pt 2):225-30.